Depresyon ve İrritabl Barsak Sendromu Birlikteliğinin Nörobiyolojisi

İrritabl barsak sendromu (İBS) yaşamı güçleştiren ve depresyonla birlikteliği çok sık karşılaşılan işlevsel bir barsak hastalığı olmasına karşın altında yatan düzenek tam olarak aydınlatılamamıştır. Tanı ölçütleri olarak değişik zamanlarda güncellenen belirti ve bulgular tanımlanmış, son olarak Roma-III olarak belirlenen ölçütlerde karar kılınmıştır. Konstipasyon-baskın, diare-baskın ya da karma irritabl barsak sendromu şeklinde görülen, irritabl barsak sendromu sürekli veya yineleyici karın ağrısı ya da karında rahatsızlık hissi ile barsak alışkanlığındaki değişkenlik, hastanın defekasyon ile rahatlaması ve yakınmaları organik yönden açıklayacak fiziksel veya laboratuar bulgularının olmayışı ile karakterizedir. İrritabl barsak sendromu olan hastalarda major depresif bozukluk sıklığı hastaların üçte ikisini kapsayacak düzeylere kadar çıkmıştır. Ayrıca, major depresif bozukluk tanısı almış olan hastalarda da irritabl barsak sendromu ek tanısının sıkça (%30) görüldüğü bilinmektedir. Uzunca bir süre bir çeşit somatizasyon bozukluğu olduğu düşünülen ve günümüzde işlevsel gastrointestinal hastalıklar içinde yer alan irritabl barsak sendromunun altında yatan düzenek beyin-barsak eksenindedir. Düşük düzeydeki mukozal yangı ile bu yangıdan kaynaklanan sitokinler irritabl barsak sendromunun patofizyolojisine ve depresyonla olan ilişkisinde önemli yer tutmaktadır. Yangısal elemanların yanısıra bireysel yatkınlıkla geliştiği düşünülen lumbosakral viseral aşırı-uyarılabilirliğin irritabl barsak sendromunun altında yatan esas patoloji olduğu öne sürülmüştür. Viseral aşırı-uyarılabilirlik gerek sitokinler, gerekse nöromediatörler aracılığı ile gelişmekte ve stres bu düzeneğin etkisini artırmaktadır. Ayrıca, bu düzenekte görevli moleküller (sitokinler, kortikotropin salgılatıcı faktör, nörokininler, monoaminler) depresyon patofizyolojisinde de rol oynamaktadır. Ağrı matriksindeki (talamus insula - prefrontal korteks) artmış etkinlik ve endojen ağrı-kesici sistemin yetersizliğinin irritabl barsak sendromu belirtilerinin abartılı hissedilmesine neden olduğu ileri sürülmüştür. Bu durum bedenin kortikal temsilinde aksamalara ve olumsuz emosyonel yaşantılara neden olmaktadır. Sitokinler, kortikotropin salgılatıcı faktör, nörokininler (substans P, nörokinin A ve nörokinin B) ile monoaminlerin (serotonin ve norepinefrin) etkileşimindeki ve nöroanatomik işlevlerdeki bireysel farklılıklar, bazı irritabl barsak sendromu hastalarında major depresyon görülürken bazılarında görülmemesini açıklayabilir. Dahası, depresyon ve anksiyete bozukluklarının eşlik ettiği irritabl barsak sendromu hastalarının belirtilerden daha çok yakındığı da bilinmektedir. Tedavi konusunda klinisyenlerin pek çok seçeneği değerlendirdiği irritabl barsak sendromuna depresyonun eşlik etmesi durumunda sağaltımda öncelikle antidepresanlara yer verilmesi önerilmektedir. Antidepresan ilaçlar arasında birinci sırada güvenlik ve yan etki profili açısından seçici serotonin geri-alım inhibitörleri yer almak

Anahtar Kelimeler:

major depresif bozukluk, irritabl barsak sendromu, komorbidite, nörobiyoloji, sağaltım

Neurobiology of Depression and Irritable Bowel Syndrome Comorbidity

Irritable bowel syndrome is a disabling functional disorder with a frequent comorbidity of depression though underlying mechanisms remain yet little understood. Various signs and symptoms have been determined as diagnostic criteria in recent years and standardized as Rome-III criteria. Irritable bowel syndrome can have constipation-dominant, diarrhea-dominant or mixed clinical presentations. Main features can be summarized as continuous and recurrent abdominal pain or discomfort associated with a change of stool frequency or consistency and usually relief of symptoms with defe-cation in the absence of physical or laboratory abnormalities indicative of an organic etiology. The frequency of major depressive disorder diagnosis reaches up to two thirds of irritable bowel syndrome patients. Moreover, the comorbidity of irritable bowel syndrome among patients with major depression is highly frequent (30%). The mechanism underlying irritable bowel syndrome which have been considered as a kind of a somatization disorder for a long time and now as a functional bowel disease is in the brain-gut axis. Low grade mucosal inflammation and cytokines originating from mucosal inflammation have important functions in the pathophysiology of irritable bowel syndrome and its comorbidity with major depression. Besides the inflammatory factors lumbosacral visceral hyperexcitability which is an individual variation is proposed as the main underlying cause of irritable bowel syndrome. Visceral hyper-excitability is mediated by cytokines and neuro-mediators and stress is known to increase the effect of this mechanism. Furthermore, molecules participating in this mechanism (e.g. cytokines, corticotrophin releasing factor, neurokinins and monoamines) play important roles in the pathophysiology of depression. Increased activation in the pain matrix (thalamus insula prefrontal cortex) and insufficiency of endogenous pain inhibitory system are regarded as possible casuses of excessive feeling of irritable bowel syndrome symptoms leading to the dysfunction in the cortical representation of bodily states and negative emotional experiences. Individual variations in the interaction of cytokines, corticotrophin releasing factor, neurokinins (substance P, neurokinin A and neurokinin B) and monoamines (serotonin and norepinephrine), and neuroanatomic functions may answer the question of "why do some irritable bowel syndrome patients experience depression and some do not?". Moreover, irritable bowel syndrome patients with comorbid depression and anxiety disorders are reported to be complaining more about their irritable bowel syndrome symptoms. Although several treatment strategies are considered by clinicians in the management of irritable bowel syndrome, it is suggested that antidepressant medications to have the priority in the treatment of irritable bowel syndrome with the comorbidity of depression. Selective serotonin re-uptake inhibitors are the drug of choice regarding thei

Keywords:

Major depressive disorder, irritable bowel syndrome, comorbidity, neurobiology, treatment,

PDF

___

Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet 2002; 360:555-564.
Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11:1019-1030.
Garakani A, Win T, Virk S, Gupta S, Kaplan D, Masand PS. Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther 2003; 10:61-67.
Talley NJ. Irritable Bowel Syndrome. Intern Med J 2006; 36:724-8.
Musial F, Hauser W, Langhorst J, Dobos G, Enck P. Psychophysiology of visceral pain in IBS and health. J Psychosom Res 2008; 64:589-597.
Drossman DA, Dumitrascu DL. Rome III: New standart for functional gastrointestinal disorders. J Gastrointest Liver Dis 2006; 15:237-241.
Celebi S, Acik Y, Deveci SE, Bahcecioglu IH, Ayar A, Demir A et al. Epidemiological features of irritable bowel syndrome in a Turkish urban society. J Gastroenterol Hepatol 2004; 19:738-743.
Yilmaz S, Dursun M, Ertem M, Canoruc F, Turhanoğlu A. The epidemiological aspects of irritable bowel syndrome in Southeastern Anatolia: a stratified randomised community-based study. Int J Clin Pract 2005; 59:361-369.
Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? J Pedi- atr Gastroenterol Nutr 2007; 45:S115-119.
Piche T, Saint-Paul MC, Dainese R, Marine-Barjoan E, Iannelli A, Montoya ML et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57:468-473.
Creed F, Guthrie E. Psychological factors in the irritable bowel syndrome. Gut 1987; 28:1307-1318.
Lydiard B. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry 2001; 62(suppl.8):38-45. disorders in humans. Gut 2002; 51(Suppl.1):i29-33.
Tollefson GD, Tollefson SL, Pederson M. Comorbid irritable bowel syndrome in patients with generalized anxiety disorder and major depression. Ann Clin Psychiatry 1991; 3:215-222.
Masand PS, Kaplan DS, Gupta S, Bhandary AN, Nasra GS, Kline MD. Major depression and irritable bowel syndrome: is there a relationship. J Clin Psychiatry 1995; 56:363-365.
Masand P, Kaplan D, Gupta S, Bhandary AN. The relationship between irritable bowel syndromeand double depression (dysthymia and major depression). Depression 1995; 3:303-308.
Blanchard EB, Scharff L, Schwarz SP, Suls JM, Barlow D. The role of anxiety and depression in the irritable bowel syndrome. Behav Res Ther 1990; 28:401-405.
Toner BB, Garfinkel PE, Jeejeebhoy KN. Psychological factors in irritable bowel syndrome. Can J Psychiatry 1990; 35:158-161.
Lydiard RB, Fossey MD, Marsh W, Ballenger JC. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics 1993; 34:229-234.
Walker EA, Gelfand AN, Gelfand MD, Katon WJ. Psychiatric diagnoses, sexual and physical victimization, and disability in patients with irritable bowel syndrome or inflammatory bowel disease. Psychol Med 1995; 25:1259-1267.
Ladep NG, Obindo TJ, Audu MD, Okeke EN, Malu AO. Depression in patients with irritable bowel syndrome in Jos, Nigeria. World J Gastroenterol 2006; 12:7844-7847.
Eker MÇ, Kasap E, Elbi H, Bor S. İrritabl Barsak Sendromu Hastalarında Cinsel- Fiziksel İstismar Sıklığı ve Major Depresif Bozukluk Öyküsü Tanı İlișkisi. Anado- lu Psikiyatri Dergisi (baskıda).
Creed F. The relationship between psychosocial parameters and outcome in irritable bowel syndrome. Am J Med 1999; 107(5A):74S-80S.
Mayer EA, Craske M, Naliboff BD. Depression, anxiety, and the gastrointestinal system. J Clin Psychiatry 2001; 62(Suppl.8):28-36.
North CS, Hong BA, Alpers DH. Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment. World J Gastroenterol 2007; 13:2020-2027.
Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 2003; 65:528-533.
Henningsen P, Herzog W. Irritable bowel syndrome and somatoform disorders. J Psychosom Res 2008; 64:625-629.
Dagleish T. The emotional brain. Nat Rev Neurosci 2004; 5: 582-589.
Bechara A, Naqvi N. Listening to your heart: introceptive awareness as a gateway to feeling. Nat Neurosci 2004; 2:102-103.
Critchley HD, Mathias CJ, Dolan RJ. Neuroanatomical basis for first and second-order representations of bodily states. Nat Neurosci 2001; 4:207-212.
Liberzon I, Phan KL, Decker LR, Taylor SF. Extended amygdala and emotional salience: a PET activation study of positive and negative affect. Neuropsychopharmacol 2003; 28:726-733.
Coplan J, Lydiard RB. Brain circuits and panic disorder. Biol Psychiatry 1998; 44:1264-1276.
Lydiard RB. Irritabl bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry 2001; 62(suppl 8):38-45.
Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122:1778-1783.
Törnblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123:1972-1979.
Gué M, Bonbonne C, Fioramonti J, Moré J, Del Rio-Lachèze C, Coméra C et al. Stress-induced enhancement of colitis in rats: CRF and arginine vasopressin are not involved. Am J Physiol 1997; 272(1 Pt 1):G84-91.
Qiu BS, Vallance BA, Blennerhassett PA, Collins SM. The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis. Nat Med 1999; 5:1178-1182.
Kiliaan AJ, Saunders PR, Bijlsma PB, Berin MC, Taminiau JA, Groot JA, et al. Stress stimulates transepithelial macromolecular uptake in rat jejunum. Am J Physiol 1998; 275(5 Pt 1):G1037-1044.
Nishida A, Miyaoka T, Inagaki T, Horiguchi J. New approaches to antidepressant drug design: cytokine-regulated pathways. Curr Pharm Des 2009; 15:1683-1687.
Khairova RA, Machado-Vieira R, Du J, Manji HK. A potential role for pro- inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol 2009; 12:561-578.
Leonard BE, Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol 2009; 24:165-175.
Varghese AK, Verdş EF, Bercik P, Khan WI, Blennerhassett PA, Szechtman H et al. Antidepressants attenuate increased susceptibility to colitis in a murine model of depression. Gastroenterology 2006; 130:1743-1753.
Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3:349-357.
De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 2004; 53:1520-1535.
Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post- dysenteric irritable bowel syndrome. Gut 2000; 47:804-811.
Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125:1651-1659.
Wheatcroft J, Wakelin D, Smith A, Mahoney CR, Mawe G, Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 2005; 17:863-870.
Mayer EA. Commentary on peripheral and central contributions to hyperalgesia in irritable bowel syndrome. J Pain 2006; 7:539-541. disorders in humans. Gut 2002; 51(Suppl 1):i29-33.
Mertz H, Morgan V, Tanner G, Pickens D, Price R, Shyr Y et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000;118:842-848.
Mayer EA, Tillisch K, Bradesi S. Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther 2006; 24:919-933.
North CS, Hong BA, Alpers DH. Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment. World J Gastroenterol 2007; 13:2020-2027.
Gorelick AB, Koshy SS, Hooper FG, Bennett TC, Chey WD, Hasler WL. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998; 275(3 Pt 1):G460-466.
Rodenbeck A, Cohrs S, Jordan W, Huether G, Rüther E, Hajak G. The sleep- improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology (Berl) 2003; 170:423-428.
Okano S, Ikeura Y, Inatomi N. Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J Pharmacol Exp Ther 2002; 300:925-931.
Bradesi S, Kokkotou E, Simeonidis S, Patierno S, Ennes HS, Mittal Y et al. The role of neurokinin 1 receptors in the maintenance of visceral hyperalgesia induced by repeated stress in rats. Gastroenterology 2006; 130:1729-1742.
Stout SC, Owens MJ, Nemeroff CB. Neurokinin(1) receptor antagonists as potential antidepressants. Annu Rev Pharmacol Toxicol 2001; 41:877-906.
Taché Y, Martinez V, Million M, Maillot C. Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome. Eur J Surg Suppl 2002; 587:16-22.
Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 2000; 97:6079-6084.
Schwetz I, McRoberts JA, Coutinho SV, Bradesi S, Gale G, Fanselow M, et al. Corticotropin-releasing factor receptor 1 mediates acute and delayed stress- induced visceral hyperalgesia in maternally separated Long-Evans rats. Am J Physiol Gastrointest Liver Physiol 2005; 289:G704-712.

ISSN: 1309-0658
Yayın Aralığı: Yılda 4 Sayı
Başlangıç: 2009
Yayıncı: Psikiyatride Güncel Yaklaşımlar

Arşiv